Results 161 to 170 of about 45,933 (222)

Everolimus induced Pneumonitis

, 2015
Everolimus (RAD 001) is an orally administered inhibitor of mTOR (mammalian target of rapamycin), a central regulator of intracellular signaling pathways involved in cell growth and proliferation, cellular metabolism and angiogenesis.
Badar, Q, Masood, N, Abbasi, A N
core  

mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment. [PDF]

Neoplasia
Nath P, Khandelwal A, Li C, Moore-Medlin T, Vasudevan SS, Alvarez VA, Franco OE, Gutkind JS, Nathan CO.   +8 more
europepmc   +1 more source

Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma. [PDF]

Int J Mol Sci
Li Y, Khan H, Demirsoy S, Younis M, Shi G, Valensi H, Bernhardt W, Lee J, Machtay M, Aregawi D, Glantz M, Giglio P, Yang S, Schell T, Walter V, Uzun Y, Olmez I.   +16 more
europepmc   +1 more source

Case Report: Acquired CDKN2A/B deletion and mTOR inhibitor resistance in TSC2-mutant metastatic epithelioid angiomyolipoma. [PDF]

Front Med (Lausanne)
He S, Yang J, Yang J, Li C, Shen J, Ye X, Liu Z, Shen W, Zheng J, Wang Y.   +9 more
europepmc   +1 more source

SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer. [PDF]

Nat Commun
Tang B, Sun R, Shao J, Wu QY, Yan Y, Wang D, Yu Z, Hu L, Chen Y, Liao C, Wei Q, Bao Y, Huang H.   +12 more
europepmc   +1 more source

Efficacy and safety of everolimus in heart transplant recipients: A meta-analysis. [PDF]

JHLT Open
Vitte SH, Luna AM, Pille JJ, Pinheiro BN, Souza MBL, Irudhayaraj CDJ, Munaretto GM.   +6 more
europepmc   +1 more source

Tumor fat composition predicts response to everolimus and supports low-dose therapy in TSC-associated renal angiomyolipomas: a multicenter prospective study. [PDF]

Front Oncol
Gao K, Duan Y, Ren B, Guo B, Su R, Gu H, Chen F, Zhang C, Wu G, Ni J.   +9 more
europepmc   +1 more source

Everolimus initiated in the neonatal period for refractory seizures associated with tuberous sclerosis complex: long-term clinical outcome. [PDF]

Epilepsy Behav Rep
Suh YA, Kim SW, Choi S, Park MS, Lee JH, In Jeong S, Yu R, Sohn YB.   +7 more
europepmc   +1 more source

Adjuvant therapy in chromophobe renal cell carcinoma: current evidence and unmet needs. [PDF]

Front Oncol
Bejjani N, Kattan J.
europepmc   +1 more source

Statement of Retraction: Everolimus ameliorates Helicobacter pylori infection-induced inflammation in gastric epithelial cells. [PDF]

Bioengineered
europepmc   +1 more source